Product Details
Synonyms
TNFRSF8, CD30, D1S166E, Ki-1
Source
PE-Labeled Human CD30, His Tag (CD0-HP2E3) is produced via site-specific conjugation of PE to Human CD30, His Tag under optimal conditions with a proprietary technology. Human CD30, His Tag is expressed from human 293 cells (HEK293). It contains AA Phe 19 - Lys 379 (Accession # NP_001234.2).
Predicted N-terminus: Phe 19
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 41.1 kDa.
Conjugate
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
Application
Evaluation of anti-CD30 CAR expression by flow cytometry. Please note that this product is NOT compatible to streptavidin detection system.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
Bioactivity-FACS

5e5 of anti-CD30 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD30, His Tag (Cat. No. CD0-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Protocol
User Reviews Publish Comment

Background Introduction
Frontier Progress
- English Name:
Tumor necrosis factor receptor superfamily member 8
- Category:
- Listed Drugs Count:
1 Details
- Clinical Drugs Count:
22 Details
- Highest R&D Stage:
Approved



















